Drug research

N-803

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as ALT-803; Anktiva; also known as IL-15N72D:IL-15RαSu/IgG1 Fc complex]), ALT-803

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint TherapyNCT03853317	IBRX	Phase 2	Terminated	2021-09-29Actual
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive GlioblastomaNCT06061809	IBRX	Phase 2	Active not recruiting	2029-12-31Estimated
A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian CancerNCT06710288	IBRX	Phase 2	Recruiting	2027-05Estimated
Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic CancerNCT04390399	IBRX	Phase 2	Active not recruiting	2025-10-13Actual
Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin LymphomaNCT07477366	IBRX	Phase 2	Not yet recruiting	2027-12Estimated
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint InNCT06745908	IBRX	Phase 3	Recruiting	2028-09Estimated
QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder CancerNCT03022825	IBRX	Phase 2, Phase 3	Active not recruiting	2024-10-01Actual

QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy

IBRXTerminatedPrimary completion: 2021-09-29 · Actual

Trial details

Registry ID: NCT03853317
Phase: Phase 2

N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma

IBRXActive not recruitingPrimary completion: 2029-12-31 · Estimated

Trial details

Registry ID: NCT06061809
Phase: Phase 2

A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer

IBRXRecruitingPrimary completion: 2027-05 · Estimated

Trial details

Registry ID: NCT06710288
Phase: Phase 2

Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

IBRXActive not recruitingPrimary completion: 2025-10-13 · Actual

Trial details

Registry ID: NCT04390399
Phase: Phase 2

Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma

IBRXNot yet recruitingPrimary completion: 2027-12 · Estimated

Trial details

Registry ID: NCT07477366
Phase: Phase 2

Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In

IBRXRecruitingPrimary completion: 2028-09 · Estimated

Trial details

Registry ID: NCT06745908
Phase: Phase 3

QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

IBRXActive not recruitingPrimary completion: 2024-10-01 · Actual

Trial details

Registry ID: NCT03022825
Phase: Phase 2, Phase 3

Regulatory dates and decisions

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.